Kidney function decreases with age and may soon limit millions of lives as the proportion of the population over 70 years of age increases. Glycogen synthase kinase 3β (GSK3β) is involved with metabolism and may have a role in kidney senescence, positioning it as a target for complications from chronic kidney disease. However, different studies suggest GSK3 has contrasting effects. In this issue of the JCI, Fang et al. explored the function of GSK3β and the interplay with lithium using human tissue and mouse models. Notably, GSK3β was overexpressed and activated in aging mice, and depleting GSK3β reduced senescence and glomerular aging. In this Commentary, we explore the similarities and differences between Fang et al. and previous findings by Hurcombe et al. These findings should prompt further study of lithium and other GSK3β inhibitors as a means of extending glomerular function in individuals with chronic kidney disease.
Jordan A. Kreidberg, Valerie A. Schumacher
Title and authors | Publication | Year |
---|---|---|
A novel GSK3β inhibitor 5n attenuates acute kidney injury
Cai YT, Li Z, Wang YY, Li C, Ma QY |
Heliyon | 2024 |
The Potential of Naturally Derived Compounds for Treating Chronic Kidney Disease: A Review of Autophagy and Cellular Senescence
Teh YM, Mualif SA, Mohd Noh NI, Lim SK |
International Journal of Molecular Sciences | 2024 |
Neuroprotection and axon regeneration by novel low-molecular-weight compounds through the modification of DOCK3 conformation.
Namekata K, Tsuji N, Guo X, Nishijima E, Honda S, Kitamura Y, Yamasaki A, Kishida M, Takeyama J, Ishikawa H, Shinozaki Y, Kimura A, Harada C, Harada T |
Cell Death Discovery | 2023 |
Interleukin-15 in kidney disease and therapeutics.
Hall G |
Current Opinion in Nephrology and Hypertension | 2023 |